Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients[J]. J Clin Oncol, 2003, 21(5): 897-906.
[2]
Sacchi S, Marcheselli L, Bari A, et al, Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma, a 16-year follow-up study[J]. Hematologica, 2008, 93(3): 398-404.
[3]
Gomez GA, Friedman M, Reese P. Occurrence of acute nonlymphocytic leukemia in a prospective randomized study of treatment for Hodgkin’s disease[J]. Am J Clin Oncol, 1983, 6(3): 319-323.
Swerdlow, SH, Campo, E, Harris, NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008: 127-129.
[6]
Pagano L , Pulsoni A , Tosti ME , et al. Acute lymphoblastic leukemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukemia[J]. Br J Haematol, 1999, 106(4):
[7]
1037-1040.
[8]
Ram R, Bonstein L, Gafter-Gvili A, et al. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon[J]. Am J Hematol, 2009, 84(4): 247-250.
[9]
Hijiya N, Ness KK, Ribeiro RC. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues[J]. Cancer, 2009, 115(1): 23-35.
Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML[J]. Leukemia, 2004, 18(1): 120.
[12]
Rowley JD, Alimena G, Carson OM, et al. A collaborative study of the relationship of the morphologyic type of acute nonlymphocytic leukemia with patient age and karyotype[J]. Blood, 1982, 59(5): 1013-1022.
[13]
Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytognetic features as well as prognostic factors[J]. Int J Hematol, 2000, 71(2): 144-152.
[14]
McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha[J]. Blood, 2005, 105: 4573-4575.
[15]
Martin-Salces M, Canales MA, de Paz R, et al. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab[J]. Leuk Res, 2008, 32(1): 199-220.
Hoyle CF, de Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC’s 9th AML trial[J]. Br J haematol, 1989, 72(1): 45-53.
Ng A, Taylor GM, Eden OB. Treatment-related leukemia: a clinical and scientific challenge[J]. Cancer Treat Rev, 2000, 26(5): 377-391.
[20]
Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome[J]. Bone Marrow Transplant, 2006, 37(2): 183-189.
